Summary
Thermo Fisher Scientific Inc. reported its first-quarter 2009 financial results, reflecting a challenging economic environment. Revenues for the quarter decreased by 12% year-over-year to $2.26 billion, primarily due to reduced customer demand amidst the global economic downturn, compounded by unfavorable currency translation effects. Operating income saw a significant decline of 35% to $190 million, with operating margins contracting from 11.4% to 8.4%. This decline was attributed to lower revenues, increased restructuring costs, and productivity pressures, partially offset by cost-saving measures and reduced amortization expenses. Despite the revenue and profitability headwinds, the company maintained a strong cash flow from operations, totaling $359 million, an increase from the prior year, largely driven by improved working capital management. The company ended the quarter with a robust cash and short-term investments balance of $1.57 billion, and sufficient borrowing capacity to meet its foreseeable cash requirements for at least the next 24 months. Management is actively implementing cost-saving measures and restructuring actions to navigate the current economic climate.
Financial Highlights
51 data points| Revenue | $2.48B |
| Cost of Revenue | $1.27B |
| Gross Profit | $988.30M |
| SG&A Expenses | $660.90M |
| Operating Expenses | $2.23B |
| Operating Income | $259.00M |
| Interest Expense | $29.60M |
| Net Income | $206.90M |
| EPS (Basic) | $0.50 |
| EPS (Diluted) | $0.49 |
| Shares Outstanding (Basic) | 415.30M |
| Shares Outstanding (Diluted) | 423.70M |
Key Highlights
- 1Consolidated revenues for Q1 2009 decreased 12% to $2.26 billion compared to Q1 2008 ($2.55 billion), driven by lower demand due to the economic downturn and unfavorable currency translation.
- 2Operating income decreased 35% to $190.1 million in Q1 2009 from $290.4 million in Q1 2008, with operating margin declining from 11.4% to 8.4%.
- 3Net income for the quarter was $148.9 million, down from $229.7 million in the prior year's comparable period, resulting in diluted EPS of $0.35 compared to $0.53.
- 4Cash flow from operating activities increased significantly to $358.7 million in Q1 2009 from $243.0 million in Q1 2008, driven by improved working capital management.
- 5The company reported $13.6 million in restructuring and other costs in Q1 2009, related to actions taken in response to the economic downturn, with further charges of approximately $22 million identified for the remainder of 2009.
- 6As of March 28, 2009, the company had $1.56 billion in cash and cash equivalents, indicating a strong liquidity position.
- 7The company completed the acquisition of Biolab for approximately $120 million on April 30, 2009, demonstrating ongoing strategic expansion.